Table 3.
Adverse events of AIIRDs patients and healthy controls who get vaccinated
| Variables | AIIRDs patients | healthy controls | p Value |
|---|---|---|---|
| No. of cases | 318 | 318 | NA |
| Infection of COVID‐19, n (%) | 1 (0.3) | 1 (0.3) | 1.000 |
| Vaccination dose, n (%) | |||
| First | 8 (2.5) | 5 (1.6) | 0.401 |
| Second | 132 (41.5) | 81 (25.5) | <0.001 |
| Third | 178 (56.0) | 232 (73.0) | <0.001 |
| Vaccine, n (%) | |||
| Sinopharm [Vero Cell]‐Inactivated COVID‐19 vaccination | 148 (46.5) | 126 (39.6) | 0.078 |
| Sinovac COVID‐19 Vaccine (Vero Cell), Inactivated | 123 (38.7) | 157 (49.4) | 0.007 |
| Sinopharm/WIBP | 70 (22.0) | 56 (17.6) | 0.164 |
| CanSinoBio | 2 (0.6) | 1 (0.3) | 1.000 |
| Zhifei Longcom | 46 (14.5) | 42 (13.2) | 0.646 |
| KCONECAVAC | 17 (5.3) | 10 (3.1) | 0.169 |
| Foreign vaccine | 3 (0.9) | 2 (0.6) | 0.499 |
| Adverse events, n (%) | |||
| None | 212 (66.7) | 222 (69.8) | 0.443 |
| Injection reaction | 34 (10.7) | 47 (14.8) | 0.122 |
| Fatigue | 26 (8.2) | 27 (8.5) | 0.886 |
| Myalgia | 24 (7.5) | 36 (11.3) | 0.104 |
| Rash | 19 (6.0) | 3 (0.9) | 0.001 |
| Arthralgia | 15 (4.7) | 0 (0.0) | <0.001 |
| Headache | 12 (3.8) | 6 (1.9) | 0.151 |
| Insomnia | 8 (2.5) | 0 (0.0) | 0.007 |
| Abdominal pain/Nausea/Vomiting | 4 (1.3) | 1 (0.3) | 0.373 |
| Low fever | 3 (0.9) | 3 (0.9) | 1.000 |
| Chills | 2 (0.6) | 2 (0.6) | 1.000 |
| Rheumatologist consulting before vaccination, n (%) | 182 (57.2) | ||
| Medication adjustment before vaccination, n (%) | 81 (25.5) | ||
| Disease activity of AIIRDs, n (%) | |||
| Aggravation | 42 (13.2) | ||
| Alleviation | 4 (1.3) | ||
| Stable | 272 (85.5) |
Note: Statistical significance was determined by Chi‐square (χ 2) test.
Abbreviations: AIIRDs, autoimmune inflammatory rheumatic diseases; NA, not available.